Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy, Sirolimus, Ruxolitinib vs PTCy, Sirolimus, MMF for GVHD Prevention
NCT06973668Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, mycophenolate mofetil in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2025; status: recruiting.
02
Drugs
ruxolitinibmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06973668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973668.